Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries.
Decentralized Clinical trials have become increasingly prevalent in the biotech and biopharmaceutical industries. Experts suggest the value of DCTs will increase by 9.8% between 2023 to 2029. Decentralized Clinical trials are cost effective and offer many benefits to researchers and participants alike, which is likely the cause of their increased usage. However, there are also some risks involved. To address this, the FDA released draft guidance to regulate DCTs and ensure participant privacy and data is protected. The guidance covers data collection and storage, investigator and sponsor responsibilities, and more.
DISCOVER MORE
![](https://fdaqrc.com/wp-content/uploads/2024/05/portfolio36-370x484.webp)
Creating a Supportive Workplace: Recognizing and Addressing Mental Health
Fostering well-being in the workplace involves raising awareness and encouraging self-care. Implementing strategies to prevent burnout and support mental health is essential for a positive, inclusive environment..
![](https://fdaqrc.com/wp-content/uploads/2024/05/portfolio35-370x484.webp)
AI in Clinical Trials: Transforming Research and Regulation
Exploring AI's Role in Streamlining Clinical Trials, Addressing Regulatory Complexity, and Balancing Ethical Considerations
![](https://fdaqrc.com/wp-content/uploads/2024/03/portfolio34-370x484.webp)
FDAQRC's Retreat and Reconnect
Our team experienced the wonders of Costa Rica while strengthening team bonds and making memories at the 2024 Face-2-Face annual meeting.
![](https://fdaqrc.com/wp-content/uploads/2024/02/portfolio35-370x484.webp)
Pharmacovigilance: Insights, Challenges, and Future Horizons
Navigating drug safety with a focus on insights, challenges, and digital innovations for a safer future.
![Employees celebrating](https://fdaqrc.com/wp-content/uploads/2024/01/portfolio34-370x484.webp)
The Future Looks Bright
Unveiling a year of achievements, growth, and industry connections - FDAQRC sets the stage for a thriving future in 2024.
![Aggie 100](https://fdaqrc.com/wp-content/uploads/2024/01/portfolio33-370x484.webp)
FDAQRC Named a 2024 Aggie 100 Honoree
FDAQRC is among the top 100 companies globally selected for the 19th annual Aggie 100 which honors the fastest-growing companies owned or led by Texas A&M Alum.
![](https://fdaqrc.com/wp-content/uploads/2023/09/portfolio32-370x484.webp)
Celebrating 14 Years of Excellence
FDAQRC recaps a year of achievements as we celebrate 14 years in business as of October 2023!
![](https://fdaqrc.com/wp-content/uploads/2023/08/portfolio31-370x484.webp)
Mastering the Difference: Monitoring and Auditing
Pharmaceutical research sponsors must make sure they follow both Monitoring and Auditing rules during their studies - so what's the difference?